Antipsychotic Drugs Market In-depth Research 2018, By Top Players AstraZeneca, Pfizer, Inc., Eli Lily and Co., Bristol- Myers Squibb, Johnson & Johnson, GlaxoSmithKline, and Allergen

Schizophrenia is the prime cause of psychosis across the globe and patients suffering with the disorder are more likely to succumb to physical and mental illness. According to the World Health Organization (WHO), over 21 million people worldwide were affected with schizophrenia in 2016. The WHO also states that one in two people suffering from schizophrenia do not receive appropriate care for the condition. This creates an opportunity for the market players in the global anti-psychotic drugs market to develop cost-effective medications for the treatment of this disease.

Furthermore, according to the National Alliance of Medical Illness in 2017, around 1.1% adults in the U.S. live with schizophrenia, while 2.6% of the population in the country suffer from bipolar disorder. On an average, 1 in 5 adults, which adds to around 43.8 million people or 18.5% of the total population in the U.S., experience some or the other kind of mental illness in a particular year. High prevalence and increasing incidence of neurological of disorders is supporting growth of the anti-psychotic drugs market.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1196

The key players dominating the global antipsychotic drugs market
- AstraZeneca
- Pfize
- Eli Lily
- Bristol- Myers Squibb
- Johnson & Johnson
- GlaxoSmithKline
- Allergen

These players are involved in developing innovative drugs for treatment of psychotic diseases with reduced side effects of the drugs to increase the consumption of the product in market. Otsuka Pharmaceuticals in November 2017 received an FDA approval for the first ever antipsychotic drug treatment Abilify MyCite, which is imbued with a digital ingestion tracking system that intends to treat Schizophrenia and acute attacks of bipolar disorder.

According to the National Survey on Drug Use and Health (NSDUH), around 13.2% of the population in the U.S. (accounting for nearly 4 million people) used an illicit drug or abused a psychotherapeutic medication in 2012. However, patent expiry of major brands over the last few years has a negative effect on market growth. Moreover, the side effects of anti-psychotics leading to tardive dyskinesia, insomnia, and several other disorders are restraining growth of the global anti-psychotic drugs market.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1196

Antipsychotic Drug Market Taxonomy:

On the basis of drug type, the global anti-psychotic drugs market is segmented into:

First-generation Drugs (Standard / Typical Antipsychotic Agents)
Thorazine (Chlorpromazine HCl)
Serentil (Mesoridazine Besylate)
Mellaril (Thioridazine HCl)
Haldol (Haloperidol)
Loxitane (Loxapine Succinate)
Trilafon (Perphenazine)
Navane (Thiothixene)
Sordinol (Clopenthixol)
Others
Second-generation Drugs (Atypical Antipsychotic Agents)
Zyprexa (Olanzapine)
Geodon (Ziprasidone)
Seroquel (Quetiapine)
Risperdal (Risperidone)
Clozaril (Clozapine)
Invega (Paliperidone)
Asendin (Amoxapine)
Latuda (Lurasidone)
Others
Third-generation Drugs
Abilify (Aripiprazole)
Others
On the basis of application, the global anti-psychotic drugs market is segmented into:

Schizophrenia
Bipolar Disorder
Dementia
Unipolar Depression
Others
On the basis of distribution channel, the global anti-psychotic drugs market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1196

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.